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Abstract In this review, the physiological rationale for
atrioventricular and interventricular delay optimization of
cardiac resynchronization therapy is discussed including
the inﬂuence of exercise and long-term cardiac resyn-
chronization therapy. The broad spectrum of both invasive
and non-invasive optimization methods is reviewed with
critical appraisal of the literature. Although the spectrum of
both invasive and non-invasive optimization methods is
broad, no single method can be recommend for standard
practice as large-scale studies using hard endpoints are
lacking. Current efforts mainly investigate optimization
during resting conditions; however, there is a need to
develop automated algorithms to implement dynamic
optimization in order to adapt to physiological alterations
during exercise and after anatomical remodeling.
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Introduction
In patients with symptomatic systolic heart failure and pro-
longed QRS duration, cardiac resynchronization therapy
(CRT) has proven to be of additional value on top of rec-
ommended medical therapy [1, 2]. Nevertheless, there
remainaconsiderablenumberofnon-responderstoCRTthat
can be as high as 30% [3]. The non-response can be partly
caused by inappropriate settings of atrioventricular (AV)
and interventricular (VV) intervals leading to persistent
atrioventricular, interventricular and intraventricular dys-
synchrony. In this review, we will discuss the physiological
and pathophysiological rationale for AV and VV optimiza-
tion followed by an overview of available optimization
methods.
Physiological electrical activation and mechanical
contraction
A coordinate contraction sequence of the heart chambers is
facilitated by rapid activation via the specialized conduc-
tion system. The cardiac action potential originates in the
sinus node and reaches the atrioventricular node (AV node)
within 100 milliseconds (ms). Slowing of conducting
through the AV node delays the onset of ventricular acti-
vation with approximately 80 ms to allow optimal atrial
contribution to ventricular preload. Rapid conduction of the
electrical impulse through the His bundle, bundle branches
and the Purkinje system activates the whole left ventricle
(LV) within 60–80 ms. Ventricular activation proceeds
from subendocardially located breakthroughs of the bundle
branches to the epicardium in a centrifugally and tangen-
tially direction [4].
Cardiac output is dependent on preload (Frank–Starling
relation), afterload and myocardial contractility. The latter
is not only inﬂuenced by neurohormones, but also depen-
dent on heart rate (staircase phenomenon or Bowditch
effect) and afterload (Anrep effect). Autonomic and neu-
rohormonal regulatory mechanisms ensure adequate car-
diac output under varying physiological conditions.
Regulation and feedback is provided by pressure sensors in
the venous and arterial vascular system [5].
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DOI 10.1007/s10741-010-9215-1Sympathetic stimulation at increasing heart rate shortens
AV delay and ventricular systole, thus preventing atrial
systole to occur against a closed mitral valve during
exercise. Shortening of ventricular systole also enables
longer ventricular ﬁlling time [6].
Pathophysiological electrical activation and mechanical
contraction
Apart from decreased myocardial contractility, there are
several other causes for decreased cardiac output in heart
failure. First, in a subset of patients, there is a disturbance
in coordination of atrial and ventricular activation with
suboptimal timing of atrial contraction (AV dyssynchrony).
The atrial contraction enhances ventricular preload by
optimizing sarcomere length of ventricular myocytes prior
to contraction which in turn increases LV stroke volume.
This booster function generates an increase in LV end-
diastolic pressure at a relatively low mean venous pressure,
thus protecting the pulmonary system from edema [7]. In
case of a shortened or prolonged AV conduction, this
preload enhancement is diminished or even lost. As the
atrial booster effect also contributes to timely closure of the
atrioventricular valves, a prolonged AV delay can also lead
to premature inversion of the atrioventricular pressure
gradient resulting in diastolic mitral regurgitation [6, 8].
Secondly, a large number of heart failure patients have
ventricular conduction disturbances, predominantly left
bundle branch block (LBBB). Although the term ‘‘block’’
suggests an abrupt interruption of conduction, there is a
spectrum of conduction abnormalities varying from a
proximal barrier to a more diffuse slowing of conduction.
As a consequence, the LV is electrically activated
throughout myocardial tissue [9]. Compared to the spe-
cialized conduction system, conduction velocity in myo-
cardial tissue is slower and the activation front spreads
preferably in a circumferential than in a perpendicular
direction [10]. This can lead to mechanical interventricular
(and intraventricular) dyssynchrony.
Because of their serial alignment and intimate anatom-
ical relationship, the mechanical properties of both ven-
tricles are inﬂuenced by each other. This close interaction
is further inﬂuenced by the interventricular septum and
pericardium. Changes in preload or afterload of one ven-
tricle alter the pressure in the other ventricle [11, 12].
Although this interaction is negligible in the healthy heart,
both systolic and diastolic interactions are augmented in
case of heart failure [13, 14]. Difference in activation
timing with the right ventricle (RV) contracting earlier than
the LV (as with LBBB) deteriorates LV function [15, 16].
Thirdly, asynchronous electrical activation of the LV in
case of LBBB leads to an altered contraction pattern.
Initially, the septum shortens during the isovolumic con-
traction time, causing an early systolic stretching of the
opposing, still non-activated posterolateral wall. Eventu-
ally, this posterolateral wall is activated late and exhibits a
late systolic or even post-systolic shortening after the
aforementioned early systolic stretching. This intraven-
tricular dyssynchrony reduces the efﬁciency of the LV
pumping function as part of the metabolic energy is wasted
in intraventricular volume shifts rather than in ventricular
ejection [17].
Atrioventricular and interventricular synchronization
in CRT
Physiological rationale for optimization
As outlined above, from a physiological point of view, it
seems reasonable to assume that correction of atrio-, inter-
and intraventricular dyssynchrony improves cardiac func-
tion and efﬁciency. In the contemporary era of CRT, this
can be achieved by programming both AV and VV timings.
It should be stressed that intrinsic AV, programmed AV
and programmed VV delay can all inﬂuence ventricular
activation and ﬁlling. Thus, depending on the device set-
tings, there can be up to three activation fronts that
potentially determine the degree of intraventricular dys-
synchrony: intrinsic right bundle branch activation, right
and left ventricular pacing, respectively (Fig. 1)[ 16].
The interaction between these three activation fronts is
illustrated in Fig. 2 showing a 12-lead electrocardiogram
(ECG) recording during three different programmed AV
delays in two patients with a CRT device. In Fig. 2a, it can
Fig. 1 Schematic pathway of different ventricular activation fronts
during normal conduction, LBBB and LBBB with biventricular
pacing. During normal conduction (left), activation of right ventricle
(RV) and left ventricle (LV) occurs through intrinsic activation, and
the time of activation (TRV and TLV) is similar. During LBBB
(middle), activation to the LV lateral wall (TLV) is delayed because of
slow myocardial conduction (TRV–LV). During biventricular pacing
(right) RV and LV lateral wall can be activated by a pacing stimulus
(TA–RVpace and TA–LVpace, respectively) if stimulation occurs before
intrinsic activation. (From Vernooy et al. [16], with permission)
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123be appreciated that there is a progressive change in QRS
morphology between the AV delays. As the intrinsic PR
interval of this patient is 156 ms, the smallest QRS com-
plex is seen at a programmed AV delay of 170 ms allowing
maximal contribution of all three activation fronts. In
Fig. 2b on contrary, no change in QRS morphology is
noted between the AV delays. The intrinsic PR interval of
this patient is 289 ms, and therefore, intrinsic conduction
does not contribute to ventricular activation.
Most patients not only have variable intra-atrial, inter-
ventricular and intraventricular conduction delays, but also
different positions of right atrial, RV and LV leads, making
it difﬁcult to predict the optimal AV and VV timings [18].
This supports the concept of an individualized and tailored
optimization of AV and VV timings.
The importance of AV and VV optimization has already
been shown in general pacing. RV single chamber pacing
disturbs the temporal relation between atria and ventricles
leading to decreased ventricular performance especially in
case of compromised cardiac function [19, 20]. In the early
nineties, the use of DDD pacing was proposed in patients
with refractory terminal heart failure and a long atrioven-
tricular delay [21]. It was anticipated that improvement in
the atrioventricular dyssynchrony by sequential atrioven-
tricular pacing would lead to improved outcome. However,
this potentially beneﬁcial effect was hampered by the
aggravated inter- and intraventricular dyssynchrony caused
by RV pacing [22]. These observations have set the base
for the current therapy of biventricular pacing.
It has been demonstrated that diastolic mitral valve
regurgitation (MR) can be reversed by AV sequential
pacing with short AV intervals [23]. The mechanism for
improvement in functional systolic MR is more complex. It
is caused by an imbalance between closing and tethering
forces on the mitral valve leaﬂets. Due to LV and mitral
valve annular dilation, there is a restrictive leaﬂet motion
requiring a higher (systolic) transmitral pressure gradient to
close the valve [24]. Moreover, LV dyssynchrony can lead
to dyscoordinate contraction of both papillary muscles
contributing to a synchronization of tethering forces [25].
In contrast, closing forces are reduced as a consequence of
decreased LV systolic function. CRT improves LV systolic
function and can result in an immediate reduction of MR
[24]. In patients with late activation of the posterior pap-
illary muscle, an acute reduction can also be observed with
CRT. Long-term resynchronization induces LV reverse
remodeling with reduction in LV and mitral annular
dimension resulting in further improvement in MR [26].
Evidence for atrioventricular optimization
The beneﬁcial effect of optimizing AV timing has been
mainly investigated in patients with an indication for per-
manent dual-chamber (right atrial and RV) pacing. The
majority of these small-scale, non-randomized studies
focus on acute hemodynamic effects of atrioventricular
optimization without evaluation of long-term morbidity
and mortality. However, these results cannot be directly
extrapolated to the CRT population [27].
In a CRT population, the PAcing THerapies in Con-
gestive Heart Failure (PATH-CHF) trial demonstrated a
signiﬁcant acute hemodynamic effect of varying the AV
delay in RV, LV and biventricular pacing [28, 29]. Inter-
estingly, the optimal AV delay for left ventricular dP/dtmax
(LV dP/dtmax) was signiﬁcantly shorter for RV and
Fig. 2 Registration of 12-lead electrocardiogram in two patients with
different intrinsic conduction during biventricular pacing with varying
AV delays. Panel A in this patient with an intrinsic PR interval of
156 ms, there is progressive change in QRS morphology between
different AV delays. At an AV delay of 170 ms, there is maximal
contribution of all 3 activation fronts resulting in the smallest QRS
complex. Panel B in case of a very long intrinsic PR interval of
289 ms, there is no change in QRS complex at different AV delays as
intrinsic conduction does not contribute to ventricular activation
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123biventricular pacing compared to LV pacing in the group of
responders. This variable acute hemodynamic response to
different AV delays was also observed in the PATH-CHF-
II trial [30]. This could be explained by the fact that during
left ventricular pacing, a left-sided atrioventricular delay is
set which should be longer to allow fusion with intrinsic
conduction coming from the normal-conducting right
bundle branch (Fig. 1).
An example of the effect of varying AV delay during
left ventricular pacing is shown in Fig. 3. At an AV delay
that is programmed 40 ms shorter than the intrinsic PR
interval (indicated as ‘‘AV1’’ in Fig. 3), there is fusion with
intrinsic right bundle branch conduction which can be
appreciated from the surface ECG and RV electrogram.
Fusion is lost with shorter AV delays (AV2, AV3 and
AV4) [31].
Atrial sensing or atrial pacing will result in different
optimal AV delays and has to be accounted for during
optimization. Compared to atrial sensing, the optimal AV
delay needs to be prolonged during atrial pacing in order to
obtain similar synchronization. In practice, one could ﬁrst
optimize AV and VV delays during atrial pacing. To get
the same resynchronization, it sufﬁces to adjust the AV
delay during atrial sensing to match QRS morphology of
the optimal AV delay obtained during atrial pacing (Fig. 4)
[32].
Only a small number of prospective and/or randomized
clinical studies compare the optimization of AV delay to an
empirical AV delay. Although these studies are small scale
and use different optimization techniques, optimization of
the AV delay shows a signiﬁcant beneﬁcial effect on acute
hemodynamic response, New York Heart Association
(NYHA) class, LV ejection fraction and brain natriuretic
peptide level [33–35].
So far, there has been no large-scale, prospective and
randomized trial evaluating the effect of AV optimization
on morbidity and mortality. Nevertheless, most large CRT
trials applied some form of AV delay optimization [1–3,
18]. It is unknown whether the beneﬁcial effects of CRT in
these trials would also be present without AV delay opti-
mization. Based on the trials’ methodology and results,
current guidelines of the European Society of Cardiology
are recommended to optimize the AV delay [36].
Evidence for interventricular optimization
The relative position of right and left ventricular leads also
inﬂuences timing of activation. As a consequence, VV
optimization may compensate for suboptimal lead place-
ment [37]. However, even in case of optimal lead place-
ment, VV delay optimization can be of importance: some
patients exhibit a signiﬁcant delay between LV pacemaker
stimulation and LV depolarization which can be counter-
acted by pre-exciting the LV pacing lead relative to the RV
pacing lead (Fig. 5).
None of the larger CRT trials included VV optimization
in their protocol, partly because this feature was not
available at time of inclusion [38]. In smaller studies, an
Fig. 3 During LV pacing, there
is fusion at AV interval 1
(AV1); however, no fusion is
observed at shorter AV intervals
(AV2, AV3 and AV4), as can be
appreciated from the 12-lead
electrocardiogram. Notice the
change in morphology of the
RV electrogram (RV EGM)
when there is no fusion with the
intrinsic RBB. (From van
Gelder et al. [31], with
permission)
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123improvement in acute hemodynamic response measured by
LV dP/dtmax [39, 40], exercise capacity [41] and echocar-
diographic left ventricular ejection fraction has been
demonstrated [42, 43]. However, the larger, randomized
DECREASE-HF trial showed a trend toward greater
reduction in left ventricular systolic diameter for the group
with simultaneous biventricular pacing compared to
sequential biventricular pacing [44], and the single-
Fig. 4 Example of the
difference in optimal paced AV
(PAV) interval and optimal
sensed AV (SAV) interval. In
this patient, CRT was optimized
during sequential AV pacing
using LV dP/dtmax. The optimal
PAV interval was 150 ms
resulting in a LV dP/dtmax of
862 mmHg/s. To determine the
optimal SAV interval, the
stimulation rate was reduced
below the intrinsic sinus rate,
and a 12-lead electrocardiogram
was recorded during
incremental shortening of the
SAV interval. At a SAV interval
of 110 ms, the QRS complex
matches the QRS complex at the
optimal PAV interval.
Determination of optimal SAV
interval is also conﬁrmed by the
LV dP/dtmax measurement
Fig. 5 Twelve-lead
electrocardiogram recording
during RV pacing (left panel),
LV pacing (middle panel) and
biventricular (BV) pacing with
VV delay of 80 ms (right
panel). The total activation
time, deﬁned as time from onset
of pacing until the end of the
QRS complex, indicated
between the two vertical dotted
lines in each panel. During RV
pacing, the total activation time
is 218 ms; however, it is
increased during LV pacing
until 274 ms. During BV
pacing, this delayed activation
can be compensated by pre-
activating LV 80 ms before RV
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123blinded, randomized RHYTHM-II trial did not ﬁnd a
beneﬁt on functional endpoints of VV optimization com-
pared to simultaneous biventricular pacing [45]. The recent
randomized, multicenter RESPONSE-HF trial evaluated
the effect of VV optimization on top of AV optimization.
Patients who were non-responders after 3 months of CRT
(with simultaneous biventricular pacing) were randomized
to either sequential biventricular pacing with VV optimi-
zation or simultaneous biventricular pacing. Non-response
was deﬁned on the basis of NYHA class and 6-min hall
walk distance. After 9 months of follow-up, the response
rate in the sequential group (n = 29) was 18.9% higher
than the simultaneous group (n = 36) [46].
In all but one of these studies [39], VV delay optimi-
zation was performed on top of prior AV optimization. In
the overall CRT population, the beneﬁt of VV optimization
compared to simultaneous biventricular pacing is relatively
small: van Gelder et al. noted a mean increase in LV
dP/dtmax of 66 mmHg/s (7%) on top of simultaneous
biventricular pacing with optimized AV delay [40]. VV
optimization may probably be more beneﬁcial in a subset
of patients who show no or little response to CRT. It can be
concluded on the basis of current data that the role of VV
optimization is still under debate. This could partly be
explained by the use of inaccurate optimization methods
with high inter- and intraobserver variability.
There is no consensus in what order to optimize the AV
and VV delays. However, in a small study, the hemody-
namic effect (measured by ﬁngerphotoplethysmography) of
simultaneously adjusting AV and VV delays was evalu-
ated. There was a curvilinear effect with a clear optimal
combination of AV and VV delays. VV optimization pro-
vided an additional, but smaller hemodynamic effect
compared to AV optimization alone [47].
Intra-individual variation in optimal AV and VV delays
The optimal AV and VV delays should not be regarded as
static values, but may vary in time and in different cir-
cumstances. In general, optimization of AV and VV delays
is performed during resting conditions in a supine or sitting
position, thus neglecting the effect of exercise. In the
healthy heart, AV conduction time shortens during exercise
as a result of increased sympathetic tone and inter- and
intraventricular activation delays are virtually absent and
not different from the resting condition [48]. This is also
the rationale for rate-adaptive atrial pacing with progres-
sive shortening of the programmed AV delay during
exercise. However, in the CRT population, it is question-
able whether rate-adaptive pacing is favorable, as the effect
of exercise on atrial and ventricular conduction is more
heterogeneous and complex [49]. Several small studies
investigating the effect of exercise on the optimal AV delay
reported mixed results: some reported individual variation
in optimal AV delay during exercise [50], others advise
prolongation of the AV delay during exercise [51] while
others notice no change in optimal AV delay [52].
VV optimization during exercise has been only spo-
radically investigated, using different optimization meth-
ods and including a limited number of patients. Laﬁtte
et al. reported a change in interventricular dyssynchrony
(deﬁned as the interventricular mechanical delay) during
bicycle exercise testing in 60% of 65 heart failure patients
[48]. In contrast, Valzania et al. showed no signiﬁcant
change in interventricular mechanical delay during dobu-
tamine stress testing [53]. Two other small studies showed
that the optimal VV delay changes during bicycle exercise
testing in about 55% of patients [52, 54]. In one study in
patients with atrial ﬁbrillation and absent intrinsic AV
conduction, a decrease in optimal VV delay with increasing
pacing rate was noted [55].
Besides the effect of exercise, optimal AV and VV
delays may also change in time as a result of reverse
remodeling. Also here, data regarding the effect of long-
term CRT on optimal AV and VV delays are limited and
contradicting. In one study, there was a decrease in optimal
AV delay and increase in LV pre-excitation in VV setting
after 6 months of CRT [56]; however, another study
showed an opposite effect after 9 months of CRT [57].
Although patient population was comparable, both trials
used different optimization methods.
The large prospective, randomized and multicenter
‘‘Frequent Optimization Study Using the QuickOpt
method (FREEDOM)’’ trial compared frequent AV and
VV optimization every 3 months using an algorithm
based on the intracardiac electrogram to standard care
with empiric programming or one-time optimization at
the discretion of the investigator. A heart failure clinical
composite score was used as primary endpoint after
12 months of follow-up. In 1,525 patients analyzed,
there was no signiﬁcant difference in primary endpoint
regardless of optimization [58].
Methods for optimization of AV and VV delays
There are numerous invasive and non-invasive methods
available to optimize both AV and VV delays. It seems
reasonable to assume that optimal delays result in highest
forward stroke volume. The ideal optimization method
should therefore be able to measure left ventricular (for-
ward) stroke volume or an equivalent in a preferably
reproducible, easy-to-perform and non-invasive way.
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First derivate of left ventricular pressure pulse
The ultimate way to determine contractile properties is
measuring the force that is generated by a muscle; how-
ever, it not possible to measure this in clinical practice. As
an alternative, the rate of left ventricular pressure change
(LV dP/dt) has been proposed [59, 60]. Pressure is deﬁned
as force per unit area and is thus related to wall force. The
rate of pressure development is inﬂuenced by the con-
tractile properties of the LV. Changes in contractility alter
the slope of the pressure curve resulting in an increased or
decreased peak rise in intraventricular pressure (dP/dtmax)
during isovolumetric contraction [61]. However, LV
dP/dt is a complex function that is not only dependent on
contractility, but also dependent on preload, afterload and
heart rate [62, 63]. However, within physiological limits,
LV dP/dtmax shows mainly dependence on contractility and
preload [64]. This properties make LV dP/dtmax a useful
instrument to evaluate the effect of both AV and VV delays
on myocardial performance.
LV dP/dt is optimally derived from a left ventricular
pressure curve obtained by a micromanometer that is
introduced endovascular into the LV [65]. We have pre-
viously described an alternative method using a 0.014 high-
ﬁdelity pressure wire (Radiwire, St. Jude Medical Inc.,
St. Paul, MN, USA) introduced either retrogradely or
transseptally into the LV [40]. In order to adequately
determine the effect of different pacing settings on LV
dP/dtmax, different protocols have been described [65, 66].
In order to overcome the inﬂuence of heart rate on LV
dP/dt, the atrium is paced at 5–10 beats above the intrinsic
rate. In patients with atrial ﬁbrillation, ventricular stimula-
tion is performed above the intrinsic rate to ensure continu-
ous capture. First, a baseline LV dP/dtmax is measured and
averaged out over several heart beats or seconds, excluding
premature and post-extrasystolic beats from analysis. After
baseline measurement, AV optimization is performed ﬁrst
during simultaneous biventricular pacing. The optimal AV
delaywiththehighestLVdP/dtmaxisselectedtoperformthe
subsequent VV optimization. The optimization procedure
should proceed under stable conditions to minimize any
inﬂuence on LV dP/dt measurement.
This method has the advantage that it is easily imple-
mented, even during the implantation procedure. Interpre-
tation is not dependent on operator skills or technical
limitations as with echocardiography. Also, it allows the
evaluation of multiple pacing sites in a short time frame.
Due to these characteristics, it is a suitable method to
evaluate the acute hemodynamic effect of different pacing
sites, either epicardially or even endocardially as has been
demonstrated in a recent case report [67]. As an example,
we implanted a left endocardial lead in a patient who
showed no clinical or echocardiographic response to stan-
dard CRT. The deﬁnite LV pacing site was determined
with optimal LV dP/dtmax during a temporary pacing study
of different endocardial sites. At long-term follow-up, there
were both clinical and echocardiographic improvements.
A disadvantage of the LV dP/dtmax optimization method
is its invasive nature. However, as only a 4-French guiding
is needed, no more complications than with standard
angiography are to be expected. Nevertheless, in our
opinion, the advantages of this invasive technique out-
weigh the relatively low risk. Alternatively, the pressure
wire can be introduced via the radial artery or even via
transseptal puncture.
The use of continuous wave Doppler imaging of the
mitral regurgitation signal is advocated as a non-invasive
alternative to determine LV dP/dtmax [68]. Importantly,
this method does not measure the true maximal LV dP/dt,
but an averaged slope of the left ventricular pressure curve
between 4 mmHg and 36 mmHg. This measure has not
been validated in an experimental physiological set-up, as
has been in case of invasively measured LV dP/dtmax [61,
63, 64]. Further, it requires the presence of a detectable
mitral regurgitation signal which is not always present
[69], has a lower temporal resolution than the invasive
method and is more laborious to average over multiple
heart beats.
Both PATH-CHF and PATH-CHF II trials used invasive
LV dP/dtmax to optimize the AV delay [30, 65]. So far,
there are no randomized controlled trials evaluating the
long-term outcome of CRT optimization by LV dP/dtmax.
Pressure–volume loops
LV pressure–volume loops can be used to calculate stroke
work deﬁned as the integrated area within the pressure–
volume loop (in mmHg mL). This index is mainly
dependent on contractility and preload with little effect of
changes in afterload [64].
To acquire pressure–volume curves, a 6-French or
7-French pressure-conductance catheter is inserted in the
LV via the femoral artery. The signals are digitized and
transformed to pressure–volume loops by dedicated soft-
ware [64, 70].
Except for its invasiveness, there are other disadvan-
tages to the use of pressure–volume loops. The relatively
inaccurate measurement of LV volume in dilated hearts
combined with a low signal-to-noise ratio make it difﬁcult
to acquire a reliable signal in heart failure patients [71].
Also, the pressure-conductance catheter needs calibrating,
has a larger size and is more expensive compared to the
micromanometer used for left ventricular pressure mea-
surements [72].
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volume loop covers both the systolic and the diastolic
phases of the cardiac cycle and incorporates both pressure
and volume changes. This makes stroke work more sensi-
tive to measure CRT-induced volume changes caused by
alteration in mitral regurgitation. Further, the internal ﬂow
fraction derived from the conductance signals can be used
to quantify LV mechanical dyssynchrony [73]. In selected
cases, this dyssynchrony index could be used to support the
indication for resynchronization therapy [74].
Compared to LV dP/dtmax, pressure–volume loops have
been used only limited in early cardiac resynchronization
studies [71]. Interestingly, when evaluating the acute
hemodynamic response to CRT by both LV dP/dtmax and
stroke work, both measures do not match in up to 50% of
the cases when using a cutoff value of 10% change to
deﬁne response to CRT [72]. A sustained long-term
hemodynamic response at 6 months has been demonstrated
in a small-scale trial [70].
Automated algorithms
Several manufacturers of CRT devices have implemented
automated algorithms to adjust AV and/or VV delays. As
the optimal delays may change in time as a consequence of
reverse remodeling after CRT as well as during exercise,
these algorithms may be of additional value. However,
adaptation during exercise can only be achieved if opti-
mization performed continuously in a closed loop conﬁg-
uration. Optimization for reverse remodeling could be
performed intermittently with automated algorithms.
Algorithms based on the intracardiac electrogram
QuickOpt. The QuickOpt algorithm (St. Jude Medical, St.
Paul, MN, USA) has been designed to optimize both AV
and VV delays using intracardiac electrograms. It has been
demonstrated that the optimal AV delay can be calculated
by measuring the time difference between onset of right
atrial activation and end of left atrial activation using the
intracardiac electrogram [75]. The QuickOpt algorithm
uses the right intra-atrial electrogram to calculate the
interatrial conduction delay. Depending on this delay, an
offset is added to determine the optimal AV delay. For VV
delay optimization, it is assumed that ventricular activation
is optimal when the two depolarization wave fronts from
right and left ventricular leads meet near the interventric-
ular septum. The optimal VV delay is based on the con-
duction delay of both intrinsic rhythm and ventricular
pacing. To measure this delay, intracardiac electrograms of
both right and left ventricular leads are used. The interval
between intrinsic activation of RV and LV leads is deﬁned
d, and the difference between RV pacing to LV sensing and
LV pacing to RV sensing is deﬁned e. The optimal VV
interval is then calculated using the formula 0.5 (d ? e).
Although the algorithm shows a strong linear correlation
with echocardiographic measurement of aortic velocity
time integral [76], there is no correlation with the optimal
VV delay determined by LV dP/dtmax [77]. The correlation
with the optimal AV and VV delays measured by echo-
cardiography (using the iterative method for AV optimi-
zation and left ventricular outﬂow tract velocity time
integral for VV optimization) is also poor [78].
The recent FREEDOM trial demonstrated that frequent
optimization using QuickOpt did not signiﬁcantly inﬂuence
outcome as deﬁned by the heart failure clinical composite
score [58]. However, these results may be due to inaccu-
racy of the QuickOpt algorithm.
SMART-AV. The SMART-AV electrogram optimiza-
tion algorithm (Boston Scientiﬁc Corporation, St. Paul,
MN, USA) is part of the Expert Ease for Heart Failure
feature and has been developed from results of large
clinical trials [3, 30, 79]. Both sensed and paced AV
delays are derived from the intracardiac electrogram and
added to the QRS duration on the surface electrocardio-
gram in either mode. A correction factor is used
depending on left ventricular lead position. This algorithm
has been compared to two echocardiographic optimization
methods (Ritter’s and aortic velocity time integral
method). In 28 patients examined, the electrogram opti-
mization method correlated signiﬁcantly better with LV
dP/dtmax than the Ritter method [80]. The ongoing ran-
domized, multicenter SMART-AV trial has been designed
to compare the effect of different atrioventricular opti-
mization methods on left ventricular remodeling. The
electrogram optimization method will be compared to
echocardiographic AV optimization (iterative method)
and a ﬁxed AV delay [81].
Peak endocardial acceleration
During the isovolumetric contraction period, the myocar-
dium generates vibrations that are transmitted throughout
the heart. The audible frequencies of these vibrations can
be appreciated as the ﬁrst (and second) heart sound. With a
microaccelerometer (SonR, Sorin Biomedica, Saluggia,
Italy) located on a lead inside the heart, it is possible to
record the full-frequency spectrum and derive the peak
endocardial acceleration (PEA). Early experimental
research has shown that changes in PEA correlates well
with changes in contractility induced by inotropic stimu-
lation [82]. The optimal AV delay determined by PEA
correlates well with those obtained by echocardiography
(Ritter’s method) [83–85]. In CRT, PEA increases signif-
icantly during LV or biventricular pacing compared to RV
pacing only [86].
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Advanced Resynchronization (CLEAR) study compared
AV and VV optimization by PEA to standard care for the
composite endpoint of NYHA class, heart failure hospi-
talization and quality of life at 12 months in 186 patients.
Patients optimized with PEA (n = 66) showed a signiﬁ-
cantly higher response rate [87].
Finger photoplethysmography
The conventional pulse oximetry probe measures the
arterial pulsations of the ﬁngertip vascular bed using a
photo detector. It is possible to measure systolic blood
pressure, pulse pressure and mean arterial pressure. As
aortic pulse pressure is inﬂuenced by stroke volume and
thus left ventricular performance, ﬁnger photoplethys-
mography may be used to optimize atrioventricular and
interventricular delay. It seems a promising tool in cardiac
resynchronization optimization because of its non-invasive
nature and high reproducibility. However, measurements
are highly inﬂuenced by waveform reﬂections in the arte-
rial system and autonomic effects on peripheral resistance.
To overcome these issues, measurements are only taken
a few beats after an atrioventricular delay change and an
algorithm is used to correct for vasodilation and/or vaso-
constriction. In patients who show a positive change in
aortic pulse pressure during CRT (invasively measured),
ﬁnger photoplethysmography (using the correction algo-
rithm described) was able to predict the AV delay with the
highest aortic pulse pressure change in up to 80% of the
patients [88].
Another technique uses a volume-clamp circuit around
the ﬁnger that dynamically follows arterial pressure
(Finapres Medical System, Amsterdam, the Netherlands)
[89]. The use of systolic blood pressure change measured
by this technique responds to changing AV intervals and is
claimed to be highly reproducible [89, 90]. Alternatively,
Nexﬁn (BMEYE B.V., Amsterdam, the Netherlands)
combines the volume-clamp technique with a dedicated
algorithm to calculate stroke volume [91]. This method
shows a good agreement with aortic valve velocity time
integral to measure changes in stroke volume and to
determine the optimal AV delay [92].
Echocardiography
Echocardiographic techniques for optimization of both AV
and VV delays have been comprehensively described in
recent review papers [27, 93, 94]. In general, echocardi-
ography is a widely available and non-invasive technique
without signiﬁcant burden for the patient. However, these
optimization techniques are subject of higher intra- and
interobserver variability than invasive measurements. Still,
echocardiography remains a cornerstone in CRT because
of its ability to evaluate response to CRT in terms of
reverse remodeling and to identify other factors that might
inﬂuence a non-response to CRT (e.g. RV failure, pul-
monary hypertension, valvular disease).
Evaluation of LV systolic function
Pulsed wave left ventricular outﬂow tract velocity time
integral (LVOT-VTI). This parameter has been used to
optimize both AV and VV delays. In a few small-scale,
uncontrolled studies, the optimal AV delay was deﬁned as
the delay with the highest stroke distance measured by
LVOT-VTI, but there is no correlation with outcome [35,
51]. In a post hoc analysis, the InSync III study compared
VV optimization using LVOT stroke volume to simulta-
neous biventricular pacing. There was only a signiﬁcant
improvement in 6-min walking test (6MWT) compared to
the control group; quality of life and NYHA class were not
signiﬁcantly different [95]. Also, the previously described
RHYTHM II ICD trial used LVOT-VTI measurements for
VV optimization, but reported no beneﬁt on functional
endpoints [45]. One small, non-randomized study used
LVOT-VTI to optimize both AV and VV delays after
3 months of non-optimized CRT and concluded that the
method was feasible, reproducible and able to improve
response to CRT [96].
Continuous wave aortic valve velocity time integral
(AV-VTI). Sawhney et al. showed in a randomized, pro-
spective trial in 40 patients that compared to an empirical
AV delay of 120 ms, AV optimization using AV-VTI
yields a signiﬁcant improvement in NYHA class, quality of
life and 6MWT [33]. Another prospective study in 40
patients compared AV optimization by AV-VTI to the
Ritter’s method and concluded that the AV-VTI method
resulted in greater systolic improvement [97]. However,
the methodology of both studies has been questioned [27].
LV dP/dt. Even though proposed as a surrogate for
invasive LV dP/dtmax measurement [68], this measurement
is not recommended as optimization method as reproduc-
ibility has been reported as suboptimal [96].
Tissue Doppler imaging (TDI). Although TDI has the
potential to assess left ventricular dyssynchrony, it is sub-
ject to high inter- and intra-observer variability [96, 98].
TDI was used to optimize VV delay and was compared to
empirical AV and VV delays by Vidal et al. in 100 patients
[99]. The optimal VV delay was deﬁned as the setting with
the greatest superposition of TDI curves of opposing LV
walls in 2-chamber and 4-chamber view. There was only a
signiﬁcant improvement in 6MWT in the optimized group.
However, 25% of patients in the optimized group did not
receive AV optimization because of atrial ﬁbrillation and
a power calculation justifying the included number of
Heart Fail Rev (2011) 16:263–276 271
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measurement of regional electromechanical delay of 18 LV
segments in the 3 apical views. The AV and VV delays
were deﬁned as optimal when the basal septal segment and
the segments containing the right and left ventricular leads
(as identiﬁed by computer tomography) were synchro-
nized. Comparing a limited number of VV intervals,
derived optimal VV delay coincided with the greatest
cardiac output as measured by thermodilution. Although
complex and time-consuming, this method is one of the
few based on the underlying physiological concept of
synchronizing the three activation fronts [100].
Evaluation of LV diastolic function
Iterative method. The AV delay is shortened by increments
of 20 ms until truncation of the A-wave on the pulsed
Doppler transmitral ﬂow pattern. Next, the AV delay is
increased again by increments of 10 ms until A-wave
truncation disappears. The latter is deﬁned as the optimal
AV delay. The iterative method was used for AV optimi-
zation in the CARE-HF trial and the aforementioned study
of Vidal et al. [99, 101].
Ritter’s formula. This method was originally proposed
for patients with complete heart block [102]. Even though
it has only been presented as an abstract and no further
validation has been published, its use has been extrapolated
to the CRT population without extensive validation. The
formula deﬁnes the optimal AV delay as the AV interval
that bridges the end of the A-wave with closure of the
mitral valve or the onset of ventricular contraction. To do
so, the time from onset of QRS complex to time of
termination of the A-wave (QA interval) is measured at
both a long (AVlong) and a short AV delays (AVshort). The
optimal AV delay is calculated from following formula:
AVopt = AVlong - (QAshort - QAlong). Ritter’s formula
has also been compared to the QuickOpt algorithm and
AV-VTI for AV optimization using LV dP/dtmax as gold
standard. This study showed that Ritter’s formula was least
accurate [80].
Mitral inﬂow velocity time integral. On the pulsed
Doppler transmitral ﬂow pattern, the VTI is calculated
representing the stroke distance of mitral inﬂow as a sur-
rogate of LV ﬁlling volume. The AV delay with the largest
VTI is considered the optimal setting. The method showed
a good correlation with optimization by LV dP/dtmax
(r = 0.96) in a small study of 30 patients [103].
Meluzin’s method. A simpliﬁed method to merge the end
of atrial contraction with mitral valve closure was proposed
by Meluzin [104]. A long AV delay is programmed and the
pulsed Doppler transmitral inﬂow pattern is recorded. The
time between end of the A-wave and onset of systolic
mitral regurgitation is calculated. This time is subtracted
from the programmed AV delay to determine the optimal
AV interval. The method was only validated in a study of
18 patients which showed a signiﬁcantly higher cardiac
output measured by thermodilution when comparing the
optimal AV delay to longer and shorter AV delays [104].
Obviously, application of this method is dependent on a
clear mitral regurgitation signal.
Evaluation of LV systolic and diastolic function
Myocardial performance index (MPI). The MPI (or Tei
index) is based on cardiac timing intervals and has been
introduced as a measurement incorporating both LV sys-
tolic and diastolic functions. The mitral-closure-to-opening
(MCO) interval is measured on the pulsed Doppler trans-
mitral ﬂow signal, and the ejection time (ET) is derived
from the pulsed Doppler LVOT ﬂow signal. As the total of
the isovolumetric contraction and relaxation time (ICT and
IRT) is obtained by subtracting ET from MCO, the index
incorporates both systolic and diastolic indices [105]. Two
small studies used MPI to optimize AV delay [106, 107]
and/or VV delay [106]. Both studies lacked a control group
and well-deﬁned endpoints.
Conclusion
Experimental physiological and pathophysiological
research supports the rationale to optimize AV and VV
delays in CRT. Although there is a spectrum of possible
optimization methods, no evident golden standard has
emerged, partly due to the lack of large-scale studies
evaluating these methods to outcome. Thus, at present, no
single method can be recommended for standard practice.
Present studies support the physiological rationale for AV
optimization, but data concerning VV optimization are still
conﬂicting. As the incremental beneﬁt of VV optimization
is relatively small, the effect is probably more of impor-
tance in a subset of CRT patients (with special attention for
non-responders). Although current efforts mainly investi-
gate optimization during resting conditions, there is a need
to develop automated algorithms to implement dynamic
optimization in order to adapt to physiological alterations
during exercise and after anatomical remodeling.
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